


Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-May-2020
 Document Type: USP Monographs
 DocId: GUID-573F59BB-B64C-4552-9EFC-17E62FA95096_4_en-US
 DOI: https://doi.org/10.31003/USPNF_M29224_04_01
 DOI Ref: bv06g

© 2025 USPC
 Do not distribute

Enalaprilat



$C_{18}H_{24}N_2O_5 \cdot 2H_2O$ 384.42

L-Proline, 1-[N-(1-carboxy-3-phenylpropyl)-L-alanyl]-, dihydrate, (S)-.

1-[N-[(S)-1-Carboxy-3-phenylpropyl]-L-alanyl]-L-proline dihydrate CAS RN®: 84680-54-6; UNII: GV007ES0R3.

» Enalaprilat contains not less than 98.0 percent and not more than 101.0 percent of $C_{18}H_{24}N_2O_5$, calculated on the anhydrous basis.

Packaging and storage—Preserve in well-closed containers.

USP REFERENCE STANDARDS (11)—

[USP Enalaprilat RS](#)

Identification—

Change to read:

A: ▲ [Spectroscopic Identification Tests \(197\)](#), [Infrared Spectroscopy: 197M](#) ▲ (CN 1-May-2020) — [NOTE—If the spectrum is not comparable to that of the Reference Standard, expose the specimen and Reference Standard to an environment of 98% relative humidity (use a chamber conditioned with a saturated solution of calcium sulfate) for 1 to 3 days to equilibrate them. Prepare dispersions from the equilibrated specimen and Reference Standard, and record the spectra.]

B: The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that of the *Standard preparation* as obtained in the Assay.

SPECIFIC ROTATION (781S): between -53.0° and -56.0° .

Test solution: 10 mg per mL, in methanol.

WATER DETERMINATION, Method I (921): between 7.0% and 11.0%.

RESIDUE ON IGNITION (281): not more than 0.2%.

Assay—

pH 3 buffer—Dissolve 1.36 g of monobasic potassium phosphate in 950 mL of water, adjust with phosphoric acid to a pH of 3.0 ± 0.1 , dilute with water to 1000 mL, and mix.

Solvent mixture—Prepare a mixture of acetonitrile, methanol, and *pH 3 buffer* (2:2:1). Adjust with phosphoric acid to a pH of 3.0 ± 0.1 , and mix.

Diluent—Prepare a mixture of *pH 3 buffer* and *Solvent mixture* (92:8), and filter.

Mobile phase—Prepare a filtered and degassed mixture of *pH 3 buffer* and *Solvent mixture* (85:15). Make adjustments if necessary (see [System Suitability](#) under [Chromatography \(621\)](#)).

Standard preparation—Dissolve an accurately weighed quantity of [USP Enalaprilat RS](#) in *Diluent* to obtain a solution having a known concentration of about 0.3 mg per mL. [NOTE—Use this solution within 24 hours.]

Assay preparation—Transfer about 30 mg of Enalaprilat, accurately weighed, to a 100-mL volumetric flask, dissolve in *Diluent*, dilute with *Diluent* to volume, and mix.

Chromatographic system (see [Chromatography \(621\)](#))—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm \times 15-cm column that contains 4- μ m packing L1 and is maintained at 70° . The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 500 theoretical plates; the tailing factor for the analyte peak is not more than 1.7; and the relative standard deviation for replicate injections is not more than 1.0%.

Procedure—Separately inject equal volumes (about 20 μ L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of $C_{18}H_{24}N_2O_5$ in the portion of Enalaprilat taken by the formula:

$$100C(r_U/r_S)$$

in which *C* is the concentration, in mg per mL, of [USP Enalaprilat RS](#) in the *Standard preparation*; and r_U and r_S are the enalaprilat peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ENALAPRILAT	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-573F59BB-B64C-4552-9EFC-17E62FA95096_4_en-US

DOI: https://doi.org/10.31003/USPNF_M29224_04_01

DOI ref: [bv06g](#)

OFFICIAL